 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 07, 2021 GLOBE NEWSWIRE -- Merus N.V. Nasdaq: MRUS Merus, the Company, we, or our, a clinical-stage oncology company developing innovative, full-length multispecific antibodies Biclonics and Triclonics, today presented clinical data on MCLA-158, including clinical responses observed in advanced head and neck squamous cell carcinoma HNSCC and preclinical data on zenocutuzumab Zeno at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. 